Who We Are
Biotech Stock Reports is a digital financial-media publication focused on the emerging edge of biotechnology — clinical- and preclinical-stage companies working in cell therapy, exosomes, and regenerative medicine. We publish watch lists, company deep-dives, and explainers designed to make a complex, fast-moving corner of the market legible to investors and the merely curious.
Biotech Stock Reports is owned and operated by DEALITHIC, a financial-technology and investor-relations firm. We believe in being direct about that: rather than present ourselves as an unaffiliated third party, we tell you plainly who is behind the publication so you can weigh our coverage with full context. See our full disclaimer for how affiliation and any compensation are handled.
What We Cover
- Regenerative medicine & cell therapy — allogeneic and autologous approaches, from spinal cord injury to rare pediatric disease.
- Exosome science — extracellular-vesicle delivery, exosome-loaded therapeutics, and the platforms building on them.
- Catalyst calendars — INDs, advisory committees, PDUFA dates, and clinical read-outs that define near-term inflection points.
- Emerging small- and micro-cap names — the earlier-stage companies that mainstream coverage tends to miss.
How We Choose Companies
Our watch lists are editorial selections, not rankings of expected return. When we build a list, we screen for three things:
- Platform — a differentiated, defensible scientific approach with preclinical or clinical validation, not a slide-deck concept.
- Catalyst — a definable, near-term inflection the market can price against.
- Asymmetry — a risk/reward profile we can describe honestly, weighing the science and balance sheet against clinical, regulatory, and financing risk.
Every company we profile is drawn from public disclosures — company filings, press releases, and regulatory records — and we date our market figures and flag what we could not independently verify. The companies we cover are early-stage and speculative by nature; we say so, every time.
Our Relationship to the Companies We Cover
We are not independent of the companies we may do business with. Because Biotech Stock Reports is operated by DEALITHIC — which provides investor-relations and related services — we may have, or may seek to establish, business relationships with companies featured on this site. Where we have been compensated by, or have a business relationship with, a company we cover, that relationship is disclosed clearly on the relevant page. Nothing we publish is investment advice.
This is the single most important thing to understand about our coverage, and we would rather over-communicate it than bury it. For the complete legal terms, please read our disclaimer.
Editorial Standards
- We source from primary disclosures and date our figures; prices and market caps are approximate and move continuously.
- We present both sides — a bull case and a bear case — and flag risks prominently.
- We do not give buy or sell recommendations, price targets, or personalized advice.
- We correct errors. If you represent a company we cover and something is inaccurate, tell us and we will fix it.
Contact
Have a correction, question, or media inquiry? Send us a note using the form below and we'll get back to you. To read our current coverage, start with the 2026 watch list.